Zamann Pharma Support logo

Siedlerstraße 7 | 68623 Lampertheim, Germany

info@zamann-pharma.com

Request an appointment now

Patient Safety Importance in 2026: How GMP Compliance and Quality Risk Management Protect Patients

Explore how GMP compliance, quality risk management, CAPA, data integrity, and contamination control connect manufacturing decisions to patient protection. This article explains what inspectors look for, which evidence matters, and how strong quality systems reduce pharmaceutical risk.
  • Blog, Quality Management System
Pharmazeutische Produktionsanlage mit GMP-Compliance, Datenintegrität, Kontaminationskontrolle und Qualitätsrisikomanagement in einer modernen Herstellungsumgebung.

Data Safety Monitoring in Pharma in 2026: DSMB Oversight Risk Signals and Trial Decisions

Explore how DSMBs review safety signals, assess benefit risk, manage interim analyses, and document trial decisions. This guide explains the evidence, controls, and inspection-ready records pharmaceutical teams need to strengthen clinical trial oversight and support regulatory compliance
  • Blog, Quality Management System
Data Monitoring Committee bei der Prüfung von Sicherheitszwischendaten, Nutzen-Risiko-Bewertung und Überwachung klinischer Studien in einem pharmazeutischen Umfeld.

Scope of Pharmacovigilance in 2026: Drug Safety Roles Skills and Career Growth

Explore how drug safety teams manage ICSRs, signals, risks, inspections, and regulatory responsibilities. This article also explains key pharmacovigilance jobs, required skills, career progression, and the evidence companies need to maintain strong compliance.
  • Blog, Quality Management System
Ein Arzneimittelsicherheitsteam überprüft Nebenwirkungsmeldungen, Daten zur Signalerkennung und Dashboards zur Überwachung nach der Marktzulassung.

Pharmacovigilance System Master File in 2026: PSMF Requirements, EU GVP Module II, QPPV, and Inspection Readiness

Explore PSMF requirements, structure, maintenance, and inspection readiness under EU GVP Module II. This article explains QPPV responsibilities, annex control, computerised systems, audit evidence, and change management practices that help drug safety teams prepare for regulatory inspections.
  • Blog, Quality Management System
PSMF structure showing QPPV responsibilities, safety data systems, PSMF annexes, quality controls, audits, and inspection-ready documentation.

Dechallenge in Pharmacovigilance in 2026: Causality Assessment and Safety Signal Review

Explore how dechallenge in pharmacovigilance supports causality assessment, safety signal review, and regulatory reporting. Learn how positive dechallenge, negative dechallenge, and rechallenge findings help pharmaceutical teams evaluate adverse drug reactions and improve Individual Case Safety Reports.
  • Blog, Quality Management System
Pharmacovigilance causality assessment workflow showing adverse drug reaction evaluation, dechallenge outcomes, and Individual Case Safety Report review

Pharma Quality Assurance as a Strategic Control System in 2026

Regulatory inspections increasingly reveal that quality failures stem from governance and oversight gaps, not technical errors. This article explains how quality systems, documentation, and inspection readiness shape compliance outcomes in regulated pharmaceutical manufacturing environments.
  • Blog, GMP, GxP, Quality Management System
Quality oversight in pharmaceuticals demonstrating GMP compliance framework, audit findings context, and inspection readiness within a pharmaceutical quality system.

Nitrosamine compounds: formation and inspection focus in 2026

This article explains how impurity formation risks emerge during pharmaceutical manufacturing and why GMP inspectors focus on formation logic, traceable decisions, and lifecycle controls. It provides an inspection-oriented view of regulatory expectations and common quality system gaps.
  • Blog, GMP, Nitrosamine
How nitrosamine impurities are formed in pharmaceutical manufacturing and reviewed during GMP inspections

Nitrosamine in pharmaceuticals: A Strategic Compliance View in 2026

Nitrosamine oversight has become a critical focus for regulators worldwide. This article explains how inspection expectations, pharmacovigilance governance, and evidence traceability shape regulatory decisions and long-term compliance strategies across pharmaceutical product lifecycles.
  • Blog, Nitrosamine
Quality and regulatory teams overseeing quality system oversight nitrosamines during pharmaceutical compliance review.

Method Validation in Pharma in 2026: GMP Inspection View

GMP inspections increasingly highlight gaps in pharmaceutical analytical validation. This article explains how regulators evaluate validation documentation, acceptance criteria, and lifecycle management, and why weaknesses in analytical method performance often escalate into formal inspection findings.
  • Blog, GMP, Validation and Qualification
GMP inspection findings caused by pharmaceutical analytical validation weaknesses, showing issues with validation documentation, acceptance criteria, and analytical method performance in regulated laboratories.

Pharma Validation as a Strategic Compliance System in 2026

This article examines pharmaceutical validation as a governance-driven compliance system, exploring lifecycle validation management, regulatory expectations, and inspection readiness. It offers strategic insight into how validation maturity, data integrity, and oversight architecture shape regulatory confidence across pharmaceutical quality systems.
  • Blog, GMP, Validation and Qualification
Pharmaceutical compliance architecture illustrating lifecycle validation management, regulatory oversight, and inspection readiness within GMP environments